Please login to the form below

Not currently logged in
Email:
Password:

Onyx appoints Amgen’s Luigi Costa as VP of Europe

Will lead plans to launch carfilzomib for multiple myeloma in Europe

Luigi Costa - Onyx PharmaceuticalsOnyx Pharmaceuticals has hired Luigi Costa as VP and head of Europe.

Costa joins the US-headquartered biopharma from Amgen where he was most recently VP and general manager of France.

In his new role he will be based at Onyx' European headquarters in Zug, Switzerland and have responsibility for leading the company's commercialisation efforts in Europe and developing its organisational structure in the region.

He will report to Dr Helen Torley, executive VP and chief commercial officer of Onyx Pharmaceuticals.

“Luigi is a proven leader in the European biopharmaceutical arena,” said Dr Torley. “His track record of success in growing established brands, such as Neulasta and Aranesp, and navigating the reimbursement environment to successfully launch new oncology products, will be key to Onyx's development of our global commercialisation plans and the potential launch of carfilzomib in Europe.”

Costa had been at Amgen since 2003 and his roles there included general manager for Switzerland and Italy as well as international head of nephrology and oncology.

Prior to joining Amgen he worked for Eli Lilly & Company between 1995 and 2003, serving in roles such as business unit director and global pricing and access manager.

7th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics